News Bristol-Myers Squibb Company

Equities

BMY

US1101221083

Market Closed - Nyse Other stock markets 04:00:02 2024-05-06 pm EDT			After market 04:25:11 pm
43.9 ^USD	-0.20%		43.92	+0.05%

02:00pm	Bristol-Myers Squibb Says Applications for Opdivo Accepted by US, European Regulators	MT
01:51pm	Bristol-Myers Gets FDA Acceptance of Review for Subcutaneous Opdivo Formulation	DJ

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Bristol-Myers Squibb Says Applications for Opdivo Accepted by US, European Regulators	08:00am	MT
Bristol-Myers Gets FDA Acceptance of Review for Subcutaneous Opdivo Formulation	07:51am	DJ
Bristol-Myers: BLA accepted for subcutaneous Opdivo	07:46am	CF
U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase)	07:00am	BU
European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite...	07:00am	BU
HSBC Adjusts Price Target on Bristol-Myers Squibb to $45 From $50	May. 01	MT
Editas Medicine, Bristol-Myers Squibb Extend Alpha-Beta T Cell Collaboration	May. 01	MT
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration	May. 01	CI
Global markets live: Adidas, Mercedes, McDonalds, Eli Lilly, PayPal, MicroStrategy, Tesla...	Apr. 30
A flurry of corporate results ahead of the Fed's rate decision	Apr. 30
ANALYST RECOMMENDATIONS : Tesla, Snap, Alphabet, Microsoft, Anglo American...	Apr. 30
Scenic Biotech Enters into Research Collaboration with Bristol Myers Squibb	Apr. 30	CI
Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion	Apr. 30	RE
J&J, Bristol Myers lose challenges to US drug price negotiation program	Apr. 29	RE
Goldman Sachs Cuts Bristol-Myers Squibb's Price Target to $56 From $60	Apr. 29	MT
Deutsche Bank Adjusts Price Target on Bristol-Myers Squibb to $53 From $55, Keeps Hold Rating	Apr. 29	MT
Repertoire® Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases	Apr. 29	PR
Repertoire® Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases	Apr. 29	CI
S&P 500 Q1 earnings estimated growth improves; stocks up for week	Apr. 26	RE
Leerink Partners Cuts Price Target on Bristol-Myers Squibb to $47 From $51	Apr. 26	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Christopher Boerner, CEO of Bristol-Myers: A pipeline of 16 treatments, with a focus on neuroscience and oncology

January 09, 2024 at 01:06 pm EST